ClinicalTrials.gg
TerminatedNCT06768658Updated Jul 2, 2025Results posted

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

A Phase 1 interventional study of TAK-951 and TAK-951 Placebo in Nausea and Vomitting, sponsored by Takeda. Terminated at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to business reasons prior to first subject dosed.

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Mar 2022, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Nausea with a site in United States — 29 open to participants now, 32 under way, 8 of them phase 3. Nausea · United States.

Enrollment
247th of 260
1 · median 86
Started
2022
with 11 others
Phase 1
23 of 290
none open now
Registered
274th of 290
by date

Among the 290 studies in Nausea with a site in United States, this one is the 247th largest by enrollment of the 260 interventional ones that give a count, is one of 12 that started in 2022, is one of 23 in phase 1, and was the 274th registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

29 of the 290 studies in Nausea with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Nausea with a site in United States, or all of them as a file.
02

Study summary

This is a study of TAK-951 in participants with cyclic vomiting syndrome (CVS).

The main aims of this study are as follows:

  • To check for side effects from treatment with TAK-951.
  • To learn how much TAK-951 participants can receive without getting side effects from it.
  • To check how much TAK-951 stays in the blood over time to work out the best dose.
  • The dose of TAK-951 will be checked to see how much stays in their blood over time.
  • To see if it is possible to give treatment at home. Participants will be given TAK-951 injected just under the skin (subcutaneous or SC).
03

Conditions studied

  • Nausea and Vomitting

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements and is eligible for the study.
  2. The participant or, when applicable, the participants' legally acceptable representative signs and dates a written or electronic, form and any required privacy authorization before the initiation of any study procedures.
  3. The participant is male or female and aged 18 to 50 years, inclusive.
  4. The participant has at least a 1-year history of CVS diagnosis based on the Rome IV diagnostic criteria.
  5. The participant has had at least 4 CVS episodes over 6 months before screening during the last 12 months.
  6. If taking eligible medications prescribed for the prophylaxis of CVS, the participant must be receiving a stable dose for at least 3 months before screening.
  7. The participant is willing and able to exclusively use the protocol rescue medications if needed.
  8. The participant has a stereotypic prodrome with onset less than or equal to (\<=) 4 hours before CVS emetic events.
  9. The participant has a (BMI) between 18 and 32 kilogram per square meter (kg/m\^2), inclusive.
  10. A male participant who is nonsterilized and sexually active with a female partner of agrees to use barrier method of (example, condom with or without spermicide) from signing of informed consent throughout the duration of the study and for 30 days after last dose OR a surgically sterile female participant, or females of nonchildbearing potential with laboratory confirmation of status (that is, follicle-stimulating hormone levels greater than (>) 40 milli-international units per milliliter [mIU/mL]) or one of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective method of contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. The participant has participated in another interventional study within 4 weeks or 5 half-lives of the study drug, whichever is longer, before the screening visit. The 4-week window will be derived from the date of the last study procedure and/or AE related to the study procedure in the previous study to the screening visit of the current study.
  2. The participant has potentially received TAK-951 in a previous clinical study, or has previously completed, discontinued, or withdrawn from this study.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (example, spouse, parent, child, sibling) or is unable to provide consent (example, incapacity or potential duress or undue influence on process).
  4. The participant has a history of significant multiple and/or severe allergies (example, food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance (including medication-induced emesis) to prescription or nonprescription drugs or food, or allergic reactions to allowed rescue medication(s).
  5. The participant has any condition or abnormality (including laboratory abnormalities), current or past, that, in the opinion of the investigator or medical monitor, would compromise the safety of the participant or interfere with or complicate the assessment of signs or symptoms of CVS.
  6. The participant uses medical or recreational cannabis more than 3 days/week or its usage triggers nausea and/or vomiting.
  7. The participant has a history of hypotension, autonomic instability, orthostatic hypotension (excluding in the context of concurrent dehydration), postural orthostatic tachycardia syndrome or a history or presence of 2 or more incidents of syncope within the last 5 years before screening.
  8. Has a history of long interval QTc, history of significant cardia arrhythmia, or a history or presence of:

    • A family history of unexplained sudden death or channelopathy; or
    • Brugada syndrome (that is, right bundle branch block pattern with ST-elevation in leads V1-V3); or
    • Second-degree atrioventricular block type 2, third degree atrioventricular block, prolonged QT interval with Fridericia correction method (QTcF) interval, hypokalemia, hypomagnesemia, or conduction abnormalities; or
    • Risk factors for Torsade de Pointes (example, heart failure, cardiomyopathy, or family history of Long QT Syndrome); or
    • Any (ECG) findings or medical history including: long or short QTcF (over 450 millisecond [msec] or less than 360 msec), bifascicular block or QRS greater than or equal to (>=120) msec or PR interval > 210 msec at screening; participants with QTcF >450 msec (up to 470 msec) taking chronic tricyclic antidepressants (>3 months) may be enrolled after consultation with the medical monitor; or o The participant has a documented history of sinus bradycardia (less than [\<] 45 beats per minute [bpm]), sinoatrial block or sinus pause >=3 seconds, or sinus node dysfunction.
  9. The participant has a history of other cardiovascular disease or cerebrovascular disease as assessed by the investigator including: essential hypertension requiring therapy or a history or presence of cerebrovascular disease such as cardiac valvulopathy, myocardial infarction, or stroke.
  10. The participant has an average semirecumbent systolic blood pressure (SBP) \< 95 or >140 or a diastolic blood pressure (DBP) \<65 millimeter of mercury (mmHg) or >90 mm Hg at screening.
  11. The participant has a screening average heart rate (HR) \<55 or >100 bpm; athletic participants with a HR \<55 bpm may be enrolled based upon the investigator's judgement provided that HR is >45 bpm and rhythm is sinus bradycardia.
  12. The participant has orthostatic hypotension defined as a decrease in systolic blood pressure (BP) >=20 mmHg or a decrease in diastolic BP >=10 mmHg after approximately 3 minutes of standing when compared with BP from the semirecumbent position, at screening.
  13. The participant has postural orthostatic tachycardia, defined as an increase of 30 bpm or HR >120 bpm after standing for approximately 3 minutes, at screening.
  14. The participant is taking medications commonly associated with tachycardia, palpitations, hypotension, or QTc prolongation as potential adverse effects (example, beta blockers, nitrates, sildenafil).
  15. The participant is taking medications prescribed for the prophylactic management of CVS with possible safety or tolerability interactions with TAK-951 as determined by the investigator(s). As above, chronic (>3 months) consistent dose of tricyclic antidepressants are allowed after consultation with the medical monitor if QTcF is \<470. The use of prochlorperazine/or promethazine as a rescue medication is explicitly prohibited until >30 hours (5 half-lives of TAK-951) after investigational product administration.
  16. The participant has a history of autonomic dysfunction.
  17. The participant has active neoplastic disease or history of neoplastic disease within 5 years of screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been definitively treated with standard of care approaches) and has received treatment in the last 5 years.
  18. The participant has a history of requiring emergency room/urgent medical treatment and intravenous fluid therapy for management of dehydration associated with clinically relevant hypotension for >2 CVS episodes in the last 6 months.
  19. The participant has a history of other conditions associated with episodic emesis including: type 1 diabetes mellitus, type 2 diabetes mellitus, gastroparesis, gastrointestinal dysmotility, inflammatory bowel disease, eosinophilic esophagitis, rumination, severe functional dyspepsia, severe gastrointestinal reflux disease, large (>3 centimeter [cm]) hiatal hernia, or unrepaired intestinal malrotation.
  20. The participant has taken opiate medications for more than 3 days in the last month.
  21. The participant has a progressive neurological disorder or a structural disorder of the brain from birth, trauma or past infection.
  22. The participant has an uncontrolled psychiatric disorder, to include history of suicide attempt, active major depressive disorder or severe panic disorder, or at the discretion of the investigator(s), for any clinically significant psychiatric history that would likely interfere with full participation in the study.
  23. The participant has started a nonpharmacologic prophylactic approach (example, acupuncture, biofeedback, chiropractic methods) within 1 month before initiation of the treatment period.
  24. The participant has a history of substance abuse.
  25. The participant has a positive pregnancy test or plans to become pregnant during the study period.
  26. The participant is a pregnant or lactating/nursing female.
  27. The participant has a history of intolerance, , or idiosyncratic reaction to TAK-951 (or any other glucose-dependent insulinotropic polypeptide [GIP] receptor agonist investigational products) or to any other ingredients of the investigational product.
  28. The participant has a clinically unstable disease or condition.
  29. The participant has any disease or condition that could compromise the function of those body systems as assessed by the investigator that could result in altered absorption, excess accumulation, or impaired metabolism or excretion of the test medications (example, mild, moderate or severe renal impairment [that is, \<90 milliliter per minute [mL/min] CrCL]) and/or altered hepatic function as assessed by the investigator (example, [ALT] >2*the [ULN], total [TB]>1.5*ULN, alkaline phosphatase >1.5*ULN).
  30. The participant has known or suspected active coronavirus disease 2019 infection as assessed by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + Placebo

    Participants will receive TAK-951 placebo-matching injection (Treatment A), subcutaneously, single dose on Day 1 in CVS Episode 1 (Period 1), followed by TAK-951 4 milligram (mg) (Treatment B), injection, subcutaneously, single dose, on Day 1 in CVS Episode 2 (Period 2), further followed by TAK-951 4 mg (Treatment B), injection, subcutaneously, single dose on Day 1 in CVS Episode 3 (Period 3), and further followed by TAK-951 placebo-matching injection (Treatment A), subcutaneously, single dose on Day 1 in CVS Episode 4 (Period 4). A washout period of at least 14 days will be maintained between each Period.

    Drug: TAK-951 · Drug: TAK-951 Placebo

  • Experimental
    Sequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mg

    Participants will receive TAK-951 4 mg (Treatment B), injection, subcutaneously, single dose on Day 1 in CVS Episode 1 (Period 1), followed by TAK-951 placebo-matching injection (Treatment A), subcutaneously, single dose on Day 1 in CVS Episode 2 (Period 2), further followed by TAK-951 placebo-matching injection (Treatment A), subcutaneously, single dose on Day 1 in CVS Episode 3 (Period 3), and further followed by TAK-951 4 mg (Treatment B), injection, subcutaneously, single dose on Day 1 in CVS Episode 4 (Period 4). A washout period of at least 14 days will be maintained between each Period.

    Drug: TAK-951 · Drug: TAK-951 Placebo

Interventions

  • TAK-951 subcutaneous injection.

  • DrugTAK-951 Placebo

    TAK-951 placebo-matching subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as an adverse event (AE) with an onset that occurs after receiving study drug. An AE was defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (example, a clinically significant abnormal vital sign or laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it was considered related to the drug.

    Time frame: Up to end of study (up to 44 weeks)

Secondary outcomes

  1. Number of Participants With Total Response

    Total response was defined as no emesis, no nausea (verbal rating scale \[VRS\] "none") and no need for rescue therapy before each time point. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome. Emesis was defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents). Nausea was defined as the desire to vomit without the presence of expulsive muscular movements.

    Time frame: Within 2, 4, and 8 hours post-dose

  2. Number of Participants With Absence of Emesis

    Absence of emesis was defined as no emesis and no need for rescue medication before each time point. Emesis was defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents).

    Time frame: Within 2, 4, and 8 hours post-dose

  3. Number of Participants With Absence of Significant Nausea

    Significant nausea was defined as a VRS greater than or equal to (\>=) moderate. Absence of nausea was defined as VRS of "none" or "mild" and no need for rescue medication before the evaluation time point. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome. Nausea was defined as the desire to vomit without the presence of expulsive muscular movements.

    Time frame: Within 2, 4, and 8 hours post-dose

  4. Peak Nausea VRS Score in All Participants

    Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

    Time frame: At 0, 1 and 2 hours post-dose

  5. Peak Nausea VRS Score in Participants Who Did Not Receive the Rescue Medication Before the Evaluation Timepoint

    Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

    Time frame: At 4 and 8 hours post-dose

  6. Change From Baseline in Nausea VRS Score in All Participants

    Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

    Time frame: At 1 and 2 hours post-dose

  7. Change From Baseline in Nausea VRS Score in Participants Who Did Not Receive the Rescue Medication Before the Evaluation Timepoint

    Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

    Time frame: At 4 and 8 hours post-dose

  8. Number of Participants With Anti-drug Antibody (ADA)

    The ADA assessment was planned to be categorized as ADA negative, ADA positive and with low or high ADA titers. ADA negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment, and ADA positive as participants who had confirmed positive ADA status in any postbaseline assessment. High ADA titer was defined as participants who had at least 1 postbaseline ADA titer greater than (\>) a cutoff planned to be determined based on the actual titer data, and Low ADA titer as participants whose postbaseline ADA titer numbers were all less than or equal to (\<=) a cutoff planned to be determined based on the actual titer data.

    Time frame: Up to end of study (up to 44 weeks)

07

Results

Posted Feb 5, 2025
Limitations and caveats
This study was terminated early and only enrolled one participant that received no treatment. Due to concerns that the participant would be at risk of being re-identified and received no treatment, no data were evaluated and collected to be reported in this study.

Participant flow

Participant flow — Overall Study
MilestoneSequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mg
Started00
Completed00
Not completed00

Outcome measures

PrimaryNumber of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as an adverse event (AE) with an onset that occurs after receiving study drug. An AE was defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (example, a clinically significant abnormal vital sign or laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it was considered related to the drug.

Time frame:
Up to end of study (up to 44 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Total Response

Total response was defined as no emesis, no nausea (verbal rating scale \[VRS\] "none") and no need for rescue therapy before each time point. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome. Emesis was defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents). Nausea was defined as the desire to vomit without the presence of expulsive muscular movements.

Time frame:
Within 2, 4, and 8 hours post-dose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Absence of Emesis

Absence of emesis was defined as no emesis and no need for rescue medication before each time point. Emesis was defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents).

Time frame:
Within 2, 4, and 8 hours post-dose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Absence of Significant Nausea

Significant nausea was defined as a VRS greater than or equal to (\>=) moderate. Absence of nausea was defined as VRS of "none" or "mild" and no need for rescue medication before the evaluation time point. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome. Nausea was defined as the desire to vomit without the presence of expulsive muscular movements.

Time frame:
Within 2, 4, and 8 hours post-dose

No measurements were reported for this outcome.

SecondaryPeak Nausea VRS Score in All Participants

Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

Time frame:
At 0, 1 and 2 hours post-dose

No measurements were reported for this outcome.

SecondaryPeak Nausea VRS Score in Participants Who Did Not Receive the Rescue Medication Before the Evaluation Timepoint

Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

Time frame:
At 4 and 8 hours post-dose

No measurements were reported for this outcome.

SecondaryChange From Baseline in Nausea VRS Score in All Participants

Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

Time frame:
At 1 and 2 hours post-dose

No measurements were reported for this outcome.

SecondaryChange From Baseline in Nausea VRS Score in Participants Who Did Not Receive the Rescue Medication Before the Evaluation Timepoint

Nausea was defined as the desire to vomit without the presence of expulsive muscular movements. This was planned to be scored using a self-reported, 4-point VRS based on verbal responses of the participants to questions, where Score 0 - none; Score 1 - mild; Score 2 - moderate; and Score 3 - severe. Higher scores mean a worse outcome.

Time frame:
At 4 and 8 hours post-dose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Anti-drug Antibody (ADA)

The ADA assessment was planned to be categorized as ADA negative, ADA positive and with low or high ADA titers. ADA negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment, and ADA positive as participants who had confirmed positive ADA status in any postbaseline assessment. High ADA titer was defined as participants who had at least 1 postbaseline ADA titer greater than (\>) a cutoff planned to be determined based on the actual titer data, and Low ADA titer as participants whose postbaseline ADA titer numbers were all less than or equal to (\<=) a cutoff planned to be determined based on the actual titer data.

Time frame:
Up to end of study (up to 44 weeks)

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events (AEs) were not collected in this study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo———
TAK-951 4 mg———

Baseline characteristics

This study was terminated early and only enrolled one participant that received no treatment. Due to concerns that the participant would be at risk of being re-identified and received no treatment, no data were evaluated and collected to be reported in this study.

Age, Continuous
Age, Continuous(years)Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mgTotal
Sex: Female, Male
Sex: Female, Male(participants)Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mgTotal
Female———
Male———
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(participants)Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mgTotal
Hispanic or Latino———
Not Hispanic or Latino———
Unknown or Not Reported———
Race (NIH/OMB)
Race (NIH/OMB)(participants)Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mgTotal
American Indian or Alaska Native———
Asian———
Native Hawaiian or Other Pacific Islander———
Black or African American———
White———
More than one race———
Unknown or Not Reported———
Region of Enrollment
Region of Enrollment(participants)Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + PlaceboSequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mgTotal
08

Study locations

1 site
  • New Phase Research & Development
    Knoxville, Tennessee 37909-1161, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jan 2023, 10 months.

Results were first posted in Feb 2025, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 10, 2025
StartActual
Mar 2, 2022
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Results first posted
Feb 5, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06768658
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Mar 2, 2022
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Results posted
Feb 5, 2025
Last update
Jul 2, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TAK-951

Start the discussion